LEXINGTON, Mass., April 6, 2021 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that James Dentzer,
President and Chief Executive Officer of Curis, will present a
company overview at the 20th Annual Needham Virtual Healthcare
Conference on Tuesday, April 13, 2021
at 10:15 am ET.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website at www.curis.com. A replay of the webcast will be
available on the Curis website for approximately 90 days following
the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 in patients with non-Hodgkin's
lymphoma both as a monotherapy and in combination with BTK
inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1
trial in patients with acute myeloid leukemia and myelodysplastic
syndromes. In addition, Curis is engaged in a collaboration with
ImmuNext for development of CI-8993, a monoclonal anti-VISTA
antibody, which is currently undergoing testing in a Phase
1a/1b trial in patients with solid
tumors. Curis is also party to a collaboration with Genentech, a
member of the Roche Group, under which Genentech and Roche are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis' website at
www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-20th-annual-needham-virtual-healthcare-conference-301262750.html
SOURCE Curis, Inc.